297 related articles for article (PubMed ID: 29352597)
1. Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.
Ortiz de Montellano PR
J Inorg Biochem; 2018 Mar; 180():235-245. PubMed ID: 29352597
[TBL] [Abstract][Full Text] [Related]
2. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes.
McLean KJ; Marshall KR; Richmond A; Hunter IS; Fowler K; Kieser T; Gurcha SS; Besra GS; Munro AW
Microbiology (Reading); 2002 Oct; 148(Pt 10):2937-2949. PubMed ID: 12368427
[TBL] [Abstract][Full Text] [Related]
3. [Research progresses of Mycobacterium tuberculosis cytochrome P450s as a potential drug target].
Lu Y; Qiao F; You XF; Yang XY
Yao Xue Xue Bao; 2014 Apr; 49(4):427-34. PubMed ID: 24974457
[TBL] [Abstract][Full Text] [Related]
4. Cytochromes P450: novel drug targets in the war against multidrug-resistant Mycobacterium tuberculosis.
Munro AW; McLean KJ; Marshall KR; Warman AJ; Lewis G; Roitel O; Sutcliffe MJ; Kemp CA; Modi S; Scrutton NS; Leys D
Biochem Soc Trans; 2003 Jun; 31(Pt 3):625-30. PubMed ID: 12773169
[TBL] [Abstract][Full Text] [Related]
5. The Mycobacterium tuberculosis cytochromes P450: physiology, biochemistry & molecular intervention.
McLean KJ; Belcher J; Driscoll MD; Fernandez CC; Le Van D; Bui S; Golovanova M; Munro AW
Future Med Chem; 2010 Aug; 2(8):1339-53. PubMed ID: 21426022
[TBL] [Abstract][Full Text] [Related]
6. Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis.
Guardiola-Diaz HM; Foster LA; Mushrush D; Vaz AD
Biochem Pharmacol; 2001 Jun; 61(12):1463-70. PubMed ID: 11377375
[TBL] [Abstract][Full Text] [Related]
7. Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv.
McLean KJ; Carroll P; Lewis DG; Dunford AJ; Seward HE; Neeli R; Cheesman MR; Marsollier L; Douglas P; Smith WE; Rosenkrands I; Cole ST; Leys D; Parish T; Munro AW
J Biol Chem; 2008 Nov; 283(48):33406-16. PubMed ID: 18818197
[TBL] [Abstract][Full Text] [Related]
8. Structure-Function Analysis of the Essential
Padayachee T; Lamb DC; Nelson DR; Syed K
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732102
[TBL] [Abstract][Full Text] [Related]
9. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
Hudson SA; McLean KJ; Munro AW; Abell C
Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
[TBL] [Abstract][Full Text] [Related]
10. Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?
Ortega Ugalde S; Boot M; Commandeur JNM; Jennings P; Bitter W; Vos JC
Appl Microbiol Biotechnol; 2019 May; 103(9):3597-3614. PubMed ID: 30810776
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol ester oxidation by mycobacterial cytochrome P450.
Frank DJ; Madrona Y; Ortiz de Montellano PR
J Biol Chem; 2014 Oct; 289(44):30417-30425. PubMed ID: 25210044
[TBL] [Abstract][Full Text] [Related]
12. Structural biology and biochemistry of cytochrome P450 systems in Mycobacterium tuberculosis.
McLean KJ; Munro AW
Drug Metab Rev; 2008; 40(3):427-46. PubMed ID: 18642141
[TBL] [Abstract][Full Text] [Related]
13. Structure Based Discovery of Inhibitors of CYP125 and CYP142 from Mycobacterium tuberculosis.
Katariya MM; Snee M; Tunnicliffe RB; Kavanagh ME; Boshoff HIM; Amadi CN; Levy CW; Munro AW; Abell C; Leys D; Coyne AG; McLean KJ
Chemistry; 2023 May; 29(29):e202203868. PubMed ID: 36912255
[TBL] [Abstract][Full Text] [Related]
14. A comparison of steroid and lipid binding cytochrome P450s from Mycobacterium marinum and Mycobacterium tuberculosis.
Child SA; Ghith A; Bruning JB; Bell SG
J Inorg Biochem; 2020 Aug; 209():111116. PubMed ID: 32473484
[TBL] [Abstract][Full Text] [Related]
15. Substrate and reaction specificity of Mycobacterium tuberculosis cytochrome P450 CYP121: insights from biochemical studies and crystal structures.
Fonvielle M; Le Du MH; Lequin O; Lecoq A; Jacquet M; Thai R; Dubois S; Grach G; Gondry M; Belin P
J Biol Chem; 2013 Jun; 288(24):17347-59. PubMed ID: 23620594
[TBL] [Abstract][Full Text] [Related]
16. Structure, function and drug targeting in Mycobacterium tuberculosis cytochrome P450 systems.
McLean KJ; Dunford AJ; Neeli R; Driscoll MD; Munro AW
Arch Biochem Biophys; 2007 Aug; 464(2):228-40. PubMed ID: 17482138
[TBL] [Abstract][Full Text] [Related]
17. Acetylene containing cyclo(L-Tyr-L-Tyr)-analogs as mechanism-based inhibitors of CYP121A1 from Mycobacterium tuberculosis.
Ortega Ugalde S; Wallraven K; Speer A; Bitter W; Grossmann TN; Commandeur JNM
Biochem Pharmacol; 2020 Jul; 177():113938. PubMed ID: 32224137
[TBL] [Abstract][Full Text] [Related]
18. CYP121, CYP51 and associated redox systems in Mycobacterium tuberculosis: towards deconvoluting enzymology of P450 systems in a human pathogen.
McLean KJ; Dunford AJ; Sabri M; Neeli R; Girvan HM; Balding PR; Leys D; Seward HE; Marshall KR; Munro AW
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1178-82. PubMed ID: 17073780
[TBL] [Abstract][Full Text] [Related]
19. The Mycobacterium tuberculosis cytochrome P450 system.
Ouellet H; Johnston JB; Ortiz de Montellano PR
Arch Biochem Biophys; 2010 Jan; 493(1):82-95. PubMed ID: 19635450
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode.
Seward HE; Roujeinikova A; McLean KJ; Munro AW; Leys D
J Biol Chem; 2006 Dec; 281(51):39437-43. PubMed ID: 17028183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
